Nang Kuang Pharmaceutical Co (TPE:1752) Cash Flow for Dividends: NT$0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1752 Nang Kuang Pharmaceutical Co Ltd TPE:1752
88 GF Score
Price NT$31.35
GF Value NT$46.62
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Nang Kuang Pharmaceutical Co Cash Flow for Dividends?

Nang Kuang Pharmaceutical Co TPE:1752 -1.10% 88 Cash Flow for Dividends is NT$0 Mil as of Dec. 2025. GuruFocus rates TPE:1752 with a GF Score™ of 88/100 and a GF Value™ of NT$46.62 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Nang Kuang Pharmaceutical Co's cash flow for dividends for the three months ended in Dec. 2025 was NT$0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Nang Kuang Pharmaceutical Co's annual payment of dividends declined from Dec. 2023 (NT$-202 Mil) to Dec. 2024 (NT$-101 Mil) and declined from Dec. 2024 (NT$-101 Mil) to Dec. 2025 (NT$-81 Mil).


Nang Kuang Pharmaceutical Co Cash Flow for Dividends Related Terms


Nang Kuang Pharmaceutical Co Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Nang Kuang Pharmaceutical Co's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nang Kuang Pharmaceutical Co Cash Flow for Dividends Chart

Nang Kuang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -151.48 -156.53 -201.98 -100.99 -80.79

Nang Kuang Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:1752
88GF Score
Nang Kuang Pharmaceutical Co Ltd TPE:1752
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nang Kuang Pharmaceutical Co Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of NT$0 Mil mean?
Nang Kuang Pharmaceutical Co (TPE:1752) has a Cash Flow for Dividends of NT$0 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Nang Kuang Pharmaceutical Co and its competitors.
Is Nang Kuang Pharmaceutical Co's Cash Flow for Dividends too high?
Nang Kuang Pharmaceutical Co's current Cash Flow for Dividends is NT$0 Mil. Overall, Nang Kuang Pharmaceutical Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nang Kuang Pharmaceutical Co's Cash Flow for Dividends compare to ISRG and BDX?
Nang Kuang Pharmaceutical Co's Cash Flow for Dividends of NT$0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Medical Devices & Instruments company?
A good Cash Flow for Dividends depends on the Medical Devices & Instruments industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Nang Kuang Pharmaceutical Co and its competitors. Nang Kuang Pharmaceutical Co's current Cash Flow for Dividends is NT$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nang Kuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co (TPE:1752) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$46.62, compared to a current price of NT$31.35 — trading 32.8% below its estimated fair value. The current Cash Flow for Dividends is NT$0 Mil. Nang Kuang Pharmaceutical Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Nang Kuang Pharmaceutical Co (TPE:1752), the current Cash Flow for Dividends is NT$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nang Kuang Pharmaceutical Co (TPE:1752) Overvalued in 2026?

Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$31.35 is trading 32.8% below its estimated GF Value™ of NT$46.62. GuruFocus considers Nang Kuang Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for TPE:1752:

  • Cash Flow for Dividends: NT$0 Mil
  • GF Value™: NT$46.62 vs. price of NT$31.35 (32.8% below fair value)
  • GF Score™: 88/100 with 3 warning signs

No single metric tells the full story. See the TPE:1752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nang Kuang Pharmaceutical Co Business Description

Address Section 8, Civic Boulevard, 5th Floor, No. 205, Nangang District, Taipei, TWN, 115
Nang Kuang Pharmaceutical Co Ltd is a Taiwan-based company, its subsidiaries are engaged in the manufacture, processing, and trading, and import and export of pharmaceuticals and medical devices. Its products are Cardiovascular system medications, Gastrointestinal medications, Nervous system drugs, Nutrition and Metabolism, Hospital infusion solution, blood products, Anticancer immunomodulators, Musculoskeletal system, and Others. Geographically, the company operates in Taiwan, China, Japan, the USA, and Other countries.
88GF Score

Get the complete analysis for TPE:1752

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.35
Price
NT$46.62
GF Value